Gilead Sciences, Inc.

- Gilead does not expect sizable M&A or meaningful new fundraising through debt or equity in the near term, as stated by CFO Andy Dickinson during the Q1 2024 earnings call. - The company has about $5 billion in cash and has leveraged back to pre-CymaBay acquisition levels. - Gilead plans to focus on ordinary course licensing deals and prudent capital allocation rather than large transactions or new debt issuance. - The firm highlights strong operating cash flow generation and disciplined expense management to fund growth and pipeline investments. - Any future capital deployment will continue to be flexible but primarily within existing cash flow and balance sheet capacity. - Management maintains a therapeutic area agnostic approach in pursuing opportunities but currently prioritizes internal pipeline execution over new external financing or M&A.

- Gilead is focused on expanding its cell therapy business, with plans to double manufacturing capacity as part of its Kite division strategy (Page 6). - The company is investing in next-generation CAR-T products and early-stage research for lymphoma and autoimmune indications (Pages 4 and 6). - There are no specific mentions of large near-term M&A transactions, but Gilead highlights disciplined capital allocation and continuing ordinary corporate development and licensing deals (Page 4). - The CymaBay acquisition is expected to add seladelpar to the portfolio with a modest revenue contribution in 2024 and more meaningful sales growth anticipated in 2025 and beyond (Pages 3 and 4). - Capital allocation priorities include maintaining flexibility, returning capital to shareholders via dividends and buybacks, and investing organically in pipeline development and commercial infrastructure (Page 3).

- Total product sales (excluding Veklury) are expected to grow 4% to 6% year over year for 2024, reaching $25.8 to $26.2 billion. - HIV sales forecasted to be roughly flat year over year in 2025 due to Medicare Part D redesign impact but overall business expected to grow. - Trodelvy sales exceeded $300 million in Q1 2024, with ongoing Phase 3 trials indicating further growth in breast, bladder, lung, and gastric cancers. Sales currently over $1 billion annually. - Cell therapy franchise (Yescarta, Tecartus) expected to expand through new treatment centers and next-generation constructs. - Seladelpar, from CymaBay acquisition, expected to contribute modestly in 2024 and more meaningfully in 2025+ after anticipated FDA approval. - Veklury sales declining due to reduced COVID-19 hospitalizations. - Continued focus on disciplined expense management to support margin and long-term growth. - Future launches and pipeline advancements (e.g., long-acting HIV regimens, cell therapies) expected to drive growth beyond 2025.

- **2024 Guidance:** - Revenue expected between $27.1B and $27.5B; base business growth (excluding Veklury) 4-6% YoY. - Gross margin guidance unchanged; R&D expected to grow at high end of low-to-mid single-digit range. - SG&A modestly higher due to CymaBay expenses but disciplined expense management continues. - Acquired IPR&D charges expected around $4.4B; total operating expenses $7B to $7.5B. - Effective tax rate ~30% due to non-deductible CymaBay charge. - Diluted EPS expected $3.45 to $3.85 (non-GAAP), excluding charges. - **2025 Outlook:** - EPS expected to be breakeven to slightly accretive from CymaBay acquisition. - HIV growth expected flat due to Medicare Part D redesign headwind, but overall business expected to grow. - Operating margin expected to improve over time due to disciplined expense management and revenue growth. - **Long-Term:** - Continued focus on disciplined expense management and efficient capital allocation. - Growth driven by HIV, oncology, liver disease, cell therapy innovation, and new product launches (e.g., seladelpar).

The provided transcript of Gilead Sciences Q1 2024 Earnings Call does not explicitly mention current or expected order book or pending orders in numerical terms. However, related insights include: - Total product sales (excluding Veklury) grew 6% year over year to $6.1 billion in Q1 2024, showing strong demand. - HIV product sales grew 4% driven by higher demand and favorable pricing. - Oncology sales were up 18%, reflecting growth in this segment. - Liver disease sales increased 9% primarily from higher demand across HCV, HBV, and HDV. - Seladelpar is expected to contribute modestly to 2024 sales, with more meaningful contribution in 2025 and beyond. - Veklury sales declined due to lower hospitalizations but remain a standard of care. - Gilead expects to launch seladelpar pending regulatory approvals, indicating upcoming order inflows. - Cell therapy and CAR-T programs have ongoing clinical trials aiming to expand future commercial opportunities. No direct figures on order backlog or pending orders are provided.